A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma
The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2014 by AHS Cancer Control Alberta.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
AHS Cancer Control Alberta
Information provided by (Responsible Party):
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT01065805
First received: December 19, 2008
Last updated: June 10, 2014
Last verified: June 2014
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The Radiotracer 18F-FLT can non-invasively assess excessive cell growth in PET scan images. Tumour growth rate is a useful indicator of tumour aggression and response to treatment. Imaging and measuring the cell growth with 18F-FLT may be useful in monitoring response to anticancer treatment.
| Condition | Intervention | Phase |
|---|---|---|
|
Brain Cancer Cancer Solid Tumor Lymphoma |
Biological: 18F-FLT |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Diagnostic |
| Official Title: | A Contiguous, Sequential Phase I/II Imaging Study of 18F-fluoro-3'-L-fluorothymidine (18F-FLT)in Patients With Known or Suspected Carcinoma of the Lung, Breast, Renal Cell, Pancreas, or Brain, and With Gastrointestinal Malignancies, Neuroendocrine Tumours or Lymphoma |
Resource links provided by NLM:
Further study details as provided by AHS Cancer Control Alberta:
Primary Outcome Measures:
- Phase I: to determine the safety of 18 F-FLT. [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
- Phase II: To determine general biodistribution of 18F-FLT and correlate 18F-FLT uptake with hENT1 expression and Ki-67 scores. [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- Phase I: To determine general biodistribution of 19F-FLT [ Time Frame: 3 years ] [ Designated as safety issue: No ]
- Phase II: to confirm safety of 18F-FLT; to determine the relative uptake of 18F-FLT (SUV, RUS, T/N); and to correlate 18F-FLT uptake with patient outcomes. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
- Phase II: to correlate 18F-FLT uptake with patient outcomes (treatment response, progression-free survival, overall survival), over the first 12 months of follow-up after completion of tx, subsequently over the remainder of the disease course [ Time Frame: 3 years ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 170 |
| Study Start Date: | February 2009 |
| Estimated Study Completion Date: | December 2015 |
| Estimated Primary Completion Date: | December 2015 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: 1
18F-FLT PET
|
Biological: 18F-FLT
Phase I: Radioactive dose of 2.59 MBq/kg (111-222 MGq)per injection. A single injection of 18F-FLT and PET scan will be permitted per patient. Phase II: Radioactive dose of 2.59 MBq/kg (100-350) MBq per injection. Up to five separate injections of 18F-FLT and PET scans will be permitted per patient |
Detailed Description:
Clinical trial is a combined Phase I/II imaging, open label, single site study in patients with known or suspected carcinoma of the lung, breast, renal cell, pancreas or brain, and with gastrointestinal malignancies, neuroendocrine tumours, or lymphoma. One 18F-FLT PET scan will be performed in 10 Phase I patients, and pre-injection and post-imaging blood work and vital signs will be collected. Up to 5 18F-FLT PET scans will be performed in 170 Phase II patients.
Eligibility| Ages Eligible for Study: | 16 Years and older (Child, Adult, Senior) |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Male or female greater than or equal to 16 years of age. If female of child-bearing potential and outside of the window of 10 days since the first day of last menstrual period, a negative pregnancy test is required.
- Patients with known primary or suspected primary, recurrent or metastatic carcinoma of the lung, breast, renal cell, pancreas or brain (including GGM, oligodendrogliomas, and brain metastases from any primary tumour) and with gastrointestinal malignancies, neuroendocrine tumours (including carcinoid and islet cell malignancies, or lymphoma, with at least one lesion >1 cm in diameter.
- Biochemical parameters as measured are required to be within 5 times the normal limits for age.
- Able and willing to follow instruction and comply with the protocol
- Provide written informed consent prior to participation in the study
- Karnofsky Performance Scale Score 50-100
Exclusion Criteria:
- Previous removal of entire tumour
- Biochemical parameters as measured outside 5 times the normal limits for age
- Unable or unwilling to follow instructions and comply with the protocol
- Unable or unwilling to provide written informed consent prior to participation in the study
- Karnofsky Performance Scale Score < 50
- Nursing or pregnant females
- Age less than 16 years
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01065805
Please refer to this study by its ClinicalTrials.gov identifier: NCT01065805
Contacts
| Contact: Lai Schrader | (780) 432 - 8464 | Lai.Schrader@albertahealthservices.ca |
Locations
| Canada, Alberta | |
| Cross Cancer Institute | Recruiting |
| Edmonton, Alberta, Canada, T6G 1Z2 | |
| Principal Investigator: Alexander J. B. McEwan, MD | |
| Sub-Investigator: M ichael B Sawyer, MD | |
| Sub-Investigator: Andrew R Belch, MD | |
| Sub-Investigator: John Mercer, BSc, MSc, PhD | |
| Sub-Investigator: Emmanuel Hudson, BMedSc, MD | |
Sponsors and Collaborators
AHS Cancer Control Alberta
Investigators
| Principal Investigator: | Alexander J. B. McEwan, MB, BS, MSc | Cross Cancer Institute |
More Information
Additional Information:
| Responsible Party: | AHS Cancer Control Alberta |
| ClinicalTrials.gov Identifier: | NCT01065805 History of Changes |
| Other Study ID Numbers: | SP-24513/DX-FLT-002 |
| Study First Received: | December 19, 2008 |
| Last Updated: | June 10, 2014 |
| Health Authority: | Canada: Health Canada |
Keywords provided by AHS Cancer Control Alberta:
|
18F-FLT Positive Emission Tomography Cancer |
Additional relevant MeSH terms:
|
Lymphoma Brain Neoplasms Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Central Nervous System Neoplasms |
Nervous System Neoplasms Neoplasms by Site Brain Diseases Central Nervous System Diseases Nervous System Diseases Alovudine Antiviral Agents Anti-Infective Agents |
ClinicalTrials.gov processed this record on September 27, 2016